Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update -U.S. Food and Drug Administration (FDA) filing of a Biologics License Application (BLA) and Priority Review for teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals; PDUFA goal date of July 2, 2021- News provided by Share this article Share this article RED BANK, N.J., Feb. 25, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial r...
Source: prnewswire.com